Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
As an adjunct to diet for your adult patients with hyperlipidemia
Address plaque head-on CRESTOR is indicated to slow the progression of atherosclerosis at any stage of the disease1
Lipitor® is not indicated to slow the progression of atherosclerosis2
CRESTOR is indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.1
For illustration only: Represents potential long-term plaque buildup in the artery.
Are your hyperlipidemic patients at increased risk at goal?
In high-risk patients in the ECLIPSE trial, CRESTOR helped more patients achieve LDL-C goal than Lipitor®3
Hypothetical patient profiles.
View study descriptionCRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non–HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.1
View head-to-head data 3 1In the STELLAR trial in patients with hyperlipidemia nearly 9 out of 10 patients met their LDL-C goal with CRESTOR 20 mg*,†,4
*Percentage of patients on CRESTOR 20 mg (n=160) achieving NCEP ATP III LDL-C goal by risk category5: High-risk–77.3%; Medium-risk–93.8%; Low-risk–94.0%. Mean baseline LDL-C: 187 mg/dL.
CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non–HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.1 1
View study description Explore the dataStudy Description X
Adapted from the ECLIPSE trial.3 ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in 1036 patients with hypercholesterolemia and CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal of <100 mg/dL at Week 24.
Study Description X
Adapted from the STELLAR trial.4 STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at Week 6. Secondary end points included achievement of NCEP ATP III goal.
Lipitor is a registered trademark of Pfizer Inc.
You may report side effects related to AstraZeneca products by clicking here.